药品详细
Tirofiban(替罗非班)
化学结构式图
中文名
替罗非班
英文名
Tirofiban
分子式
C22H36N2O5S
化学名
(2S)-2-(butane-1-sulfonamido)-3-{4-[4-(piperidin-4-yl)butoxy]phenyl}propanoic acid
分子量
Average: 440.597
Monoisotopic: 440.234492962
Monoisotopic: 440.234492962
CAS号
144494-65-5
ATC分类
B01A 抗血栓药
药物类型
small molecule
阶段
approved
商品名
同义名
基本介绍
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.
生产厂家
- Medicure international inc
封装厂家
- Baxter International Inc.
- Ben Venue Laboratories Inc.
- Guilford Pharmaceuticals
- Iroko Pharmaceuticals
- Medicure International Inc.
- Merck & Co.
参考
| Synthesis Reference | Not Available |
| General Reference | Not Available |
剂型
规格
化合物类型
| Type | small molecule |
| Classes |
|
| Substructures |
|
适应症
药理
| Indication | For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. | ||||||
| Pharmacodynamics | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. When administered intravenously, tirofiban inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the recommended regimen, >90% inhibition is attained by the end of the 30-minute infusion. Tirofiban has been recently shown in patients with unstable angina to reduce ischemic events at 48 hours following infusion when compared to standard heparin therapy. | ||||||
| Mechanism of action | Tirofiban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Platelet aggregation inhibition is reversible following cessation of the infusion of tirofiban. | ||||||
| Absorption | Not Available | ||||||
| Volume of distribution |
|
||||||
| Protein binding | 65% | ||||||
| Metabolism |
Metabolism appears to be limited.
|
||||||
| Route of elimination | It is cleared from the plasma largely by renal excretion, with about 65% of an administered dose appearing in urine and about 25% in feces, both largely as unchanged tirofiban. | ||||||
| Half life | 2 hours | ||||||
| Clearance |
|
||||||
| Toxicity | Not Available | ||||||
| Affected organisms |
|
||||||
| Pathways |
|
理化性质
| Properties | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| State | solid | ||||||||||||||||||||||||||||||||||||||||||
| Experimental Properties |
|
||||||||||||||||||||||||||||||||||||||||||
| Predicted Properties |
|
||||||||||||||||||||||||||||||||||||||||||
药物相互作用
| Drug | Interaction |
|---|---|
| Abciximab | Additive effects. Concomitant use is contraindicated. |
| Eptifibatide | Additive effects. Concomitant use is contraindicated. |
| Ginkgo biloba | Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided. |
| Treprostinil | The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Tirofiban. Monitor for increased bleeding during concomitant thearpy. |
食物相互作用
Not Available
收藏